Browse

Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Chris Kroeger sees MapLight's drug as competitive based on the "totality of data."

Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market

A biotech with a bispecific antibody from China and a little-known San Diego startup with a BTK inhibitor from Gossamer Bio have each signed reverse mergers to take their experimental medicines ont…